Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

MUROMONAB-CD3 for Transplant rejection: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 12 adverse event reports in the FDA FAERS database where MUROMONAB-CD3 was used for Transplant rejection.

Most Reported Side Effects for MUROMONAB-CD3

Side Effect Reports % Deaths Hosp.
Post transplant lymphoproliferative disorder 22 19.3% 3 14
Infection 16 14.0% 6 3
Cytomegalovirus infection 13 11.4% 5 4
Cytomegalovirus oesophagitis 10 8.8% 1 0
Drug resistance 10 8.8% 1 0
Duodenitis 10 8.8% 1 1
Gastritis 10 8.8% 1 1
Weight decreased 10 8.8% 1 0
Chest pain 9 7.9% 1 0
Cytomegalovirus chorioretinitis 9 7.9% 0 0
Cytomegalovirus infection reactivation 9 7.9% 1 0
Encephalitis 9 7.9% 1 0
Gastric fistula 9 7.9% 1 0
Gastric ulcer 9 7.9% 1 0
Gastrointestinal ulcer 9 7.9% 1 0

Other Indications for MUROMONAB-CD3

Immunosuppressant drug therapy (38) Prophylaxis against transplant rejection (20) Prophylaxis against graft versus host disease (13) Immunosuppression (12) Product used for unknown indication (11) Bone marrow conditioning regimen (8) Allogenic stem cell transplantation (5)

Other Drugs Used for Transplant rejection

METHYLPREDNISOLONE (968) RITUXIMAB (615) TACROLIMUS (477) HUMAN IMMUNOGLOBULIN G (327) PREDNISONE (300) MYCOPHENOLATE MOFETIL (297) LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN (273) ECULIZUMAB (176) THYMOCYTE IMMUNE GLOBULIN NOS (173) BORTEZOMIB (145)

Related Pages

MUROMONAB-CD3 Full Profile All Transplant rejection Drugs MUROMONAB-CD3 Demographics MUROMONAB-CD3 Timeline